SUMMARY The effects of isoprenaline on the induction of supraventricular tachycardia by programmed stimulation were studied in 67 patients to see whether they correlated with spontaneous catecholamine mediated symptoms during exercise testing and Holter monitoring. Thirty seven control patients (group 1) did not have spontaneous arrhythmias either during exercise testing or Holter monitoring. Thirty patients (group 2) had documented exercise or stress related supraventricular tachycardias-that is paroxysmal junctional tachycardia (24) or atrial arrhythmia (6). Programmed electrical stimulation was performed before and during the infusion of isoprenaline. No group 1 patient developed sustained supraventricular tachycardia during isoprenaline infusion. In 21 patients with paroxysmal junctional tachycardia and all the patients with atrial arrhythmias electrical stimulation during isoprenaline infusion produced the same tachycardia that had been seen during exercise testing and Holter monitoring. Changes in electrophysiological variables and the concentrations of serum potassium were not associated with the induction of supraventricular tachycardia by isoprenaline. Infusion of isoprenaline safely facilitated the induction of supraventricular tachycardia by programmed stimulation in patients who had spontaneously occurring catecholamine mediated symptoms.
Although isoprenaline is known to facilitate the induction of ventricular tachycardia' 2 it has rarely been used to aid the electrical induction of supraventricular tachycardia.
We report the results obtained when small infusions of isoprenaline were given to patients who did not have clinical supraventricular tachycardia and in whom standard stimulation techniques failed to induce tachycardia and to patients who did have spontaneous but non-inducible tachycardia.
Patients and methods

PATIENTS
Sixty seven patients who underwent programmed stimulation of the heart were classified according to the presence or absence of clinical and inducible supraventricular tachycardias.
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Accepted for publication 1 November 1988 Group 1 Group 1 consisted of 37 patients aged from 12 to 67 (average 45) who had no clinical history of tachycardia. Seventeen had underlying heart disease: dilated cardiomyopathy (three), hypertrophic cardiomyopathy (five), coronary heart disease (two), mitral valve prolapse (two), congenital heart disease (four), valve disease (one). Four patients in group 1 had Wolff-Parkinson-White syndrome. Electrophysiological studies were performed to investigate the cause of syncope (12) or dizziness (17) . These studies, which included ventricular stimulation, were also completed in eight patients with underlying heart disease (four cases) or were performed to assess the severity of Wolff-Parkinson-White syndrome (four cases). Twenty four hour Holter monitoring showed no evidence of supraventricular arrhythmias (three patients had atrial extrasystoles). No tachycardia or atrial extrasystoles were seen during upright bicycle exercise testing at an initial workload of 25 W, with subsequent increases of 25 W every two minutes. Exercise continued until exhaustion or the onset of symptoms. 348 No supraventricular tachycardia was induced by programmed stimulation in the basal state.
Group 2 Group 2 consisted of 30 patients aged from 15 to 80 (average 45) who had been admitted with supraventricular tachycardias and who had been included in a group of about 160 patients with supraventricular tachycardia studied in the laboratory over four years (1983 to 1987) . Group 2a consisted of 24 patients with paroxysmal regular junctional reciprocating tachycardia and group 2b consisted of six patients with paroxysmal atrial arrhythmias-atrial fibrillation (two), atrial flutter (one), and atrial tachycardia (three). All the patients in group 2 had tachycardia induced by exercise or psychological stress. In most an electrocardiographic recording of the tachycardia was available. None the less, only eight of the 29 patients who exercised on the bicycle showed supraventricular arrhythmias during exercise. There were frequent salvoes of atrial extrasystoles (five), atrial tachycardia (one), and paroxysmal junctional tachycardia (two) immediately after exercise. Twenty four hour Holter monitoring in all the patients showed a paroxysmal junctional tachycardia in nine patients and atrial tachycardia in three patients. Nine patients had underlying heart disease: mitral valve prolapse (six), valvar heart disease (one), and dilated cardiomyopathy (two). Eight patients had Wolff-Parkinson-White syndrome. Electrophysiological study was performed to investigate the mechanism of the tachycardia (23) or syncope associated with tachycardia (seven).
All patients had normal serum concentrations of potassium. Cardioactive drugs were stopped at least five half lives before the study.
ELECTROPHYSIOLOGICAL STUDIES
Electrophysiological studies were performed in nonsedated patients in the post-absorptive state after they had given their informed consent. All patients were in normal sinus rhythm at the time of study. Right heart catheterisation was performed through the femoral vein with three 6 or 7 French multielectrode catheters. Electrograms were recorded from the right atrium, the atrioventricular (AV) junction (His bundle electrogram), and the coronary sinus. Atrial and ventricular stimulation was performed with a programmable digital stimulator (Explorer 2000 Ela Medical) that delivered rectangular pulses lasting 1-8 ms at twice the diastolic threshold. Intracardiac electrograms and electrocardiographic leads I, III, and VI were simultaneously displayed on a multichannel oscilloscope (Siemens recording system) and recorded at a paper speed of25 to 100 mm/s. Arterial blood pressure was measured by sphygmomanometry every five minutes.
We used the following protocol of programmed stimulation: (a) incremental atrial pacing up to the onset of type 1 second degree block; (b) atrial extrastimulus testing during sinus rhythm (S2) and atrial pacing at cycle lengths of 600 and 400 ms (S1 S2); (c) incremental ventricular pacing up to the onset of retrograde ventriculoatrial (VA) second degree or higher grades of ventriculoatrial block (maximal pacing rate 220 beats/min); (d) ventricular extrastimulus techniques up to S3 during sinus rhythm and ventricular pacing (cycle lengths of 600 and 400 ms) with two stimuli. In 21 patients the plasma concentration of potassium was measured after programmed stimulation in 21 patients.
Isoprenaline infusion was started at 0 5 Mg/min and adjusted to increase the basal heart rate by at least 20%. In all patients the heart rate was increased to at least 100 beats/min (maximum of 150 beats/min). During the infusion we repeated the stimulation protocol and measured the serum concentration of potassium at comparable cycle lengths. The effective refractory periods were determined at a cycle length of 400 ms. The amount of isoprenaline required to induce the desired changes in heart rate ranged from 6 to 20 jg.
Heart rate and blood pressure were monitored continuously throughout the study.
DEFINITION OF TERMS
Non-sustained supraventricular tachycardia: at least five consecutive atrial extrasystoles, but less than one minute of tachycardia reproducibly induced.
Sustained supraventricular tachycardia: tachycardia that lasted more than one minute.
Non-sustained ventricular tachycardia: at least five consecutive ventricular extrasystoles, but reproducibly induced for less than one minute.
Sustained ventricular tachycardia: tachycardia that lasted more than one minute.
STATISTICAL ANALYSIS
We used a two tailed t test for independent or paired samples. Numerical data are presented as mean ( 
SD).
Results Tables 1-3 show the results of electrophysiological testing in all the study groups.
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SERUM CONCENTRATIONS OF POTASSIUM
The serum concentration of potassium fell significantly in group 1.
INDUCED SUPRAVENTRICULAR TACHYCARDIA
In the basal state sustained supraventricular tachycardia could not be induced by programmed stimulation in any patient; a non-sustained atrial arrhythmia was induced in five patients from group 1 and in eight from group 2 and a non-sustained paroxysmal junctional tachycardia was induced in five patients from group 2. After infusion of isoprenaline sustained supraventricular tachycardia could not be initiated in any group 1 patients, even when they had had nonsustained supraventricular tachycardia during the basal study. Non-sustained atrial tachycardia was induced in one group 1 patient who did not have inducible arrhythmia in the basal state.
After isoprenaline sustained junctional tachycardia was induced in 21 patients in group 2a either spontaneously (three) or by programmed stimulation (18) . There were 13 re-entrant tachycardias in the atrioventricular node and eight re-entrant tachycardias conducted retrogradely through a Kent bundle. Non-sustained junctional tachycardia was induced in one patient.
After isoprenaline, clinical sustained atrial tachycardia could be reproduced in six patients in group 2 either spontaneously (three) or by programmed stimulation (three). There was one atrial flutter, two atrial fibrillations, and three atrial tachycardias.
In group 2 the sensitivity of the isoprenaline test, defined as the percentage of inducible sustained supraventricular tachycardia, was 90%. Specificity, (TABLE 5) We analysed certain variables in patients in group 2a and group 1 to discover whether any of them correlated with the induction of junctional tachycardia.
After isoprenaline we did not find any differences between groups 1 and 2a for variation in cycle length, AH interval, heart rate at which anterograde type 1 second degree block developed, and serum potassium. In group 2a retrograde block was significantly more common after electrophysiological testing in the basal state (p < 0-05) and after isoprenaline (p < 0-02) (fig) . However, the occurrence of a fast retrograde conduction after isoprenaline did not assist the prediction of the induction of junctional tachycardia: seven patients from group 1 without retrograde conduction in the basal state showed retrograde conduction on isoprenaline at stimulation rates of up to 200/min. The sensitivity of the isoprenaline test defined as the percentage ofpatients in whom retrograde conduction developed at stimulation rates of 200/min was 86% in group 2a, but its specificity, defined as the percentage that developed retrograde conduction at rates of < 200 beats/min was 38% in group 1. isoprenaline infusion; one of these patients had spontaneous salvoes of atrial tachycardia. One patient from group 2 had spontaneous nonsustained uniform ventricular tachycardia (130 beats/min). The systematic programmed ventricular stimulation induced non-sustained multiform ventricular tachycardia in the basal state in two patients in group 1 and four in group 2. After isoprenaline, none of the patients from group 1 and only two from group 2 had induced multiform non-sustained ventricular tachycardia.
Discussion
We found that the isoprenaline test assisted the diagnosis of catecholamine mediated junctional tachycardias (sensitivity 90%, specificity 100%).
The role of the sympathetic nervous system in supraventricular arrhythmias was suggested by clinical observations, the bicycle exercise test, and 24 hour Holter monitoring.5 Adrenergic supraventricular tachycardias are induced by exercise or stress, and they occur predominantly during the day.
There have been few studies of adrenergic supraventricular tachycardia. The role of adrenergic effects, which modify the refractory periods of accessory pathways, has been studied mainly in Wolff-Parkinson-White syndrome.467 Coumel et al reported Holter studies to evaluate the role of the sympathetic nervous system in arrhythmias other than in the Wolff-Parkinson-White syndrome.5 In our study, the sensitivity of Holter monitoring for the diagnosis of adrenergic supraventricular arrhythmia was poor (40%). The sensitivity of exercise testing for triggering a supraventricular tachycardia was also poor (40%). Moreover, when tachycardia occurs immediately after exercise during Holter monitoring, as in cases 15 and 22, the mechanism could be adrenergic or vagal. 8 These findings indicated the desirability of a pharmacological test that induced trachycardias caused by adrenergic mechanisms. In patients with exercise induced ventricular arrhythmias isoprenaline often caused identical arrhythmia.9 ' Isoprenaline produces f adrenergic stimulation, which affects the electrophysiological properties of the single cell and the intact heart in several ways.'-" In single fibres isoprenaline increased the spontaneous phase IV depolarisation of sinus node, facilitated the development of triggered automaticity, and shortened the action potential duration. In intact hearts, isoprenaline increased the sinus rate and the rate of ectopic pacemakers, accelerated atrioventricular conduction, and shortened the refractoriness of the atrioventricular node and His-Purkinje system. It might be difficult to establish whether the tachycar-dia induced by isoprenaline resulted from direct stimulation of cardiac f adrenoreceptors or from reflex changes, which might be in the opposite direction, depending on whether the blood pressure rose or fell."2 Vagal tone may be increased, as in three of our patients, or reduced by the haemodynamic effects of isoprenaline.
An alternative approach to the adrenergic initiation of tachycardia is to use atropine to withdraw the vagal effect, leaving the action of natural catecholamine unopposed. A pharmacological test could also be based on adrenaline, noradrenaline, and atropine.
The frequency with which isoprenaline facilitates the induction of atrial tachycardia has not been reported before. In our study there were six patients with an adrenergic mediated tachycardia that could be reproduced by infusion of isoprenaline and electrophysiological stimulation. The spontaneous occurrence of the arrhythmia in three of them may implicate enhanced automaticity. Non-sustained atrial tachycardia was induced in only one of the controls. Thus infusion of isoprenaline seems a useful provocative test to detect adrenergic paroxysmal atrial tachycardia.
There are few studies of the frequency with which isoprenaline facilitates the induction of junctional tachycardia. Levy In patients who did not have Wolff-ParkinsonWhite syndrome or spontaneous arrhythmias, we did not find that infusion of isoprenaline increased the induction of non-sustained atrial or ventricular tachycardia. The mechanism by which isoprenaline facilitates the induction of junctional tachycardia remains unknown. Triggered automaticity and delayed after-depolarisation were possible mechanisms for the tachycardia that occurred during isoprenaline infusion in the two patients with spontaneous junctional tachycardia. In the study of Krikler et al incessant attacks of tachycardia without antecedent PR prolongation were induced by isoprenaline and were attributed to the speeding of the sinus rate, which might sufficiently shorten the refractory periods of the atrial and anomalous pathways to permit retrograde conduction up the anomalous pathway to the atrium thus causing an echo beat and tachycardia.'5 In most of our patients (n = 19), the arrhythmias required an initiation beat and were stopped by one or two stimuli, suggesting that isoprenaline infusion facilitated reentry by reducing the refractoriness and increasing conduction velocity and the myocardium. The induction of catecholamine dependent reentrant tachycardia has been attributed to a rapid anterograde and/or retrograde conduction'4 18; this explanation was not confirmed in our study.
Because adrenaline can reproduce stress hypokalaemia'920 another mechanism by which isoprenaline might have facilitated reentry was by a reduction in intracellular potassium. The fall in serum potassium, however, was similar in groups 1 and 2, so this mechanism cannot account for the facilitation of arrhythmia. Infusion of isoprenaline can safely be used to facilitate the induction of supraventricular tachycardia in patients who have spontaneous supraventricular tachycardia, when sympathetic stimulation is enhanced.
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